NUTRAQ acquired by ORKLA

Coloplast has reached an agreement to acquire Atos Medical from the private equity firm PAI Partners. his transaction marks a major strategic exit for PAI Partners, which acquired the company in 2016. During PAI’s five-year ownership, Atos Medical more than doubled in size, transforming from a laryngectomy specialist into a diversified ENT leader with a significant foothold in the tracheostomy market. The rationale for the acquisition is highly strategic for Coloplast, as it adds a new chronic care segment to its existing portfolio

The acquisition of HRA Pharma by Perrigo signifies the "crowning achievement" of the acquirer’s structural transformation into a pure-play consumer self-care leader. The strategic rationale for this transaction centers on a "portfolio-premium" maneuver, merging the target’s high-growth, margin-accretive branded assets with the acquirer’s massive expert direct go-to-market platform. This structural alignment provides the organization with the scientific talent and regulatory hardware necessary to dominate high-potential European markets and accelerate the "Rx-to-OTC" pipeline globally

Intech Medical, a global leader in the manufacturing of orthopedic surgical instruments and implants, has entered into an agreement to be acquired by Montagu Private Equity. The transaction marks the exit of Eurazeo (specifically its mid-cap subsidiary) and Andera Partners, who have held a majority stake in the French group since 2017.

Partners Group acquired 100% of Pharmathen from BC Partners, which had acquired the company in 2015. During its ownership, BC Partners invested over €250 million in R&D and new FDA-approved production facilities, nearly doubled the employee headcount, and repositioned Pharmathen from a traditional European generics manufacturer into a technology-driven global leader in complex drug delivery. The transaction is expected to support Pharmathen's continued growth, particularly into the US market. BC Partners was advised by Jefferies (financial) and Kirkland & Ellis (legal)

DiaSorin has finalized the acquisition of Luminex Corporation, an operation designed to fundamentally strengthen the group’s competitive positioning within the molecular diagnostics and life sciences sectors. The strategic rationale for this transaction centers on a "technology-integration" play, merging the target's world-class multiplexing platform with the group’s dominant immunodiagnostics infrastructure. This fusion effectively creates a specialized powerhouse in the diagnostic arena, providing the organization with the scientific talent and hardware portfolio required to address the increasing global demand for multi-assay testing panels

Naxicap Partners acquired a majority stake (~80%) in Groupe Lagarrigue from Ardian and iXO Private Equity. The management team reinvested to hold the remaining ~20%. Naxicap prevailed in a competitive auction process managed by Edmond de Rothschild Corporate Finance, beating out offers from IK Investment Partners and Cobepa. The transaction is financed through a unitranche debt facility (likely provided by ArcMont AM) combined with a PIK note (CIC Private Debt), including significant capex lines to fund future external growth

CVC acquired a majority stake in Cooper-Vemedia from Charterhouse. The transaction, valued at EUR2.2 billion, was won in a competitive process against a PAI/Ontario Teachers' consortium. The acquisition reflects CVC's appetite for high-cash-flow businesses with low capital intensity (Capex ~EUR10M). The goal is to pursue a buy-and-build strategy across Europe.

Siparex ETI has entered into exclusive negotiations to acquire a majority stake in Winncare, marking the first investment of its Siparex ETI 5 fund. This transaction follows a successful period of ownership by IDI, which originally took control of the group in 2014 and supported a doubling of the company,s size through international expansion. In this new capital structure, IDI is exiting its majority position but remains a minority investor, alongside the management team led by President Philippe Chêne, who continues to drive the group,s strategic vision

Montagu Private Equity entered into exclusive negotiations to acquire a majority stake in IMV Technologies from Qualium Investissement. Montagu prevailed in a competitive process against CVC Capital Partners. This transaction marks the fifth LBO for the company, which was previously backed by Idi, Ofi Private Equity, and Sparring Capital. The deal underpins the company's leadership in the niche market of animal genetics and its strong export capabilities.

For the first time since its founding in 1913, Proteor has opened its capital to institutional investors through a primary Owner Buy-Out (OBO). Ardian Growth and BNP Paribas Développement have injected €24 million (a mix of convertible bonds and equity) to support the group's next phase of expansion. The founding Archambeaud family maintains clear majority control of the group. The strategic rationale for this primary round is to provide Proteor with the financial firepower to execute major international build-ups, specifically the $17 million acquisition of the US-based assets of Freedom Innovations